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Aim: To evaluate the role of computed tomography (CT) perfusion imaging in patients with hepatocellular carcinoma (HCC).
Materials and methods: Seventeen patients (9 men, 8 women) with newly diagnosed HCC, proven by biopsy, were evaluated with
256-slice helical CT. Perfusion parameters of blood flow (BF), blood volume (BV), arterial perfusion (AP), portal perfusion (PP), and
hepatic perfusion index (HPI) were calculated in the normal liver parenchyma and HCC samples.
Results: A total of 21 histologically proven HCC lesions were evaluated from CT perfusion images. BF, BV, AP, and HPI values were
shown to be significantly higher (P < 0.05) in the HCC lesions than in the normal liver parenchyma. Conversely, PP values were found
to be significantly lower (P < 0.05) in HCC relative to liver parenchyma.
Conclusion: CT perfusion imaging has the ability to evaluate tumor assessment, characterization, and neoangiogenesis in HCC.
Key words: Computed tomography, perfusion imaging, hepatocellular carcinoma

1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy worldwide, with a very high mortality (1). Only
20% of patients are suitable for curative resection at the time
of diagnosis (2). HCCs are highly vascular and the status
of angiogenesis correlates with the disease progression and
prognosis. Therefore, assessment of tumor vascularity is
important for determining the course of the disease and the
response to treatment. Functional computed tomography
with perfusion imaging (CT perfusion imaging) is a
noninvasive technique that provides a quantitative
assessment of tumor vascularity using various parameters.
The aim of our study was to evaluate the role of CT perfusion
imaging in patients with HCC.
2. Materials and methods
2.1. Patients
We included in our prospective study 18 consecutive
patients with newly diagnosed HCC, proven by biopsy.
Subjects who had clinical evidence of liver and/or renal
and/or cardiac failure, history of hypersensitivity to
iodinated contrast agents, or acute/chronic portal vein
* Correspondence: akkanrad@hotmail.com

thrombosis were excluded. The final study group consisted
of 17 patients (9 men, 8 women; mean age: 58 ± 6 years,
range: 47–72 years). In this group, 14 patients had a
solitary tumor, 2 patients had 2 tumors, and 1 patient had
3 tumors. This prospective study was approved by our
institutional review board and written informed consent
was obtained before CT perfusion imaging.
2.2. CT perfusion imaging
Multidetector CT perfusion imaging was performed in 17
patients with 256-slice helical CT (SOMATOM Definition
Flash CT, Siemens Medical Solutions, Erlangen, Germany).
Before CT scanning, the medial cubital vein or basilic vein
of each patient was catheterized with an 18-gauge cannula
for the administration of a contrast agent. An unenhanced
scan was obtained first. Each subject was intravenously
injected with 50 mL of contrast material (Omnipaque
350, Amersham Health, Cork, Ireland) with a flow rate of
5 mL/s followed by 60 mL of saline flush at 5 mL/s. The
scan parameters for this perfusion were as follows: field
of view, 320 mm; matrix size, 512 × 512; tube voltage, 120
kV; and tube current, 150 mA. Finally, dynamic enhanced
scanning (80 kV and 100 mAs) was performed.
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The functional CT images were then transferred to a
commercial workstation (Syngo, Leonardo Workstation,
Siemens) and the data were analyzed using dedicated
perfusion software, which generated a quantitative map of
the liver perfusion displayed on the monitor by means of
a color scale.
2.3. CT image analysis
Two radiologists, with 8 years and 5 years of experience
in abdominal CT, reviewed the CT perfusion images and
measured the CT perfusion parameters. The region of
interest (ROI) was drawn manually in the center of the
aorta, portal vein, and spleen. In each patient the slice
having the largest diameter of liver tumor was selected to
measure CT perfusion parameters. The ROIs were placed
within the tumor at least 1 cm away from the tumor border
and necrotic tissue, and the vessels were not included in
the ROI to the greatest extent possible. ROIs were also
placed on liver parenchyma and perfusion parameters
were calculated.
Computed tomographic perfusion values of blood
flow (BF), blood volume (BV), arterial perfusion (AP),
portal perfusion (PP), and hepatic perfusion index (HPI)
were calculated in the normal liver parenchyma and HCC
samples.
2.4. Statistical analysis
Two radiologists with 8 years and 5 years of experience
in abdominal CT evaluated CT perfusion images by
consensus. Student’s t-test was used to determine the
significance between the CT perfusion parameter values
of the lesion and the liver parenchyma. The values of CT
perfusion parameters were expressed as mean ± SD and
P < 0.05 was considered statistically significant. Statistical
analysis was performed using SPSS 16.0 (SPSS Inc.,
Chicago, IL, USA).
3. Results
There were a total of 21 histologically proven HCC lesions;
14 patients had a single lesion, 2 had 2 lesions, and 1 had
3 lesions. The size of the lesions ranged from 2.4 to 7.3 cm
(mean: 4.9 cm) in diameter.
On CT perfusion images BF, BV, AP, and HPI values
were shown to be significantly higher (P < 0.05) in the HCC
lesions than in the surrounding liver parenchyma (Figure).
Conversely, PP values were found to be significantly lower
(P < 0.05) in HCC relative to liver parenchyma (Table).
4. Discussion
HCC is one of the most vascular solid tumors. It mostly
occurs in patients with chronic hepatitis and cirrhosis.
The outcome of patients with untreated HCC is very
poor (3). One of the important features in staging is
tumor vascularity. Conventional cross-sectional imaging
methods such as CT and magnetic resonance, as well as
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imaging with ultrasonography, may not be adequate for
detection of tumor-associated vascularity (4). A dysplastic
lesion gradually converts to HCC in carcinogenesis. During
this process, a gradual increase in neovascularized arteries
occurs. CT perfusion imaging is a recently developed
noninvasive imaging technique that allows both qualitative
and quantitative evaluation of tumor vascularity.
Functional imaging technique with CT allows
quantification of tissue hemodynamics by using several
perfusion parameters in normal and pathologic tissues.
This technique involves multiple serial CT acquisitions
acquired with a short interval between each acquisition
(5). CT perfusion imaging is performed after the
administration of iodinated contrast material. Contrast
material is transported to the tissue by blood flow and
an exchange between the intravascular space and the
extravascular interstitial space occurs. Detailed analysis
of liver hemodynamics is obtained by serial images with
CT perfusion imaging; hepatic blood flow and portal
blood flow are calculated using a color-encoded display of
parameters derived from the time–density curve.
Functional evaluation has been done for the cirrhotic
liver, liver malignancy, infectious liver disease, and other
different diseases (6). Perfusion parameters significantly
differed when comparing normal tissue versus tumoral
tissue. Blood flow, volume, and permeability values are
high because of the development of arteriovenous shunts,
dilated capillary beds, and hyperpermeable vessels during
neoangiogenesis. CT perfusion was also found to be
useful for monitoring anticancer agents against tumor
vasculature and having the ability to show changes in
tumor vasculature. Response to the treatment is better
assessed by alterations in tumor vascularity. CT perfusion
imaging has also shown potential in predicting response to
antiangiogenic therapies, as demonstrated in HCC, rectal
tumors, and other body tumors (7–9).
Sahani et al. reported that CT perfusion imaging
is a useful modality to assess tumor vascularity and
angiogenesis in advanced HCC (10). Ippolito et al. showed
that all the quantitative parameters evaluated [hepatic
perfusion, tissue blood volume, HPI, AP, PP, and time
to peak (TTP)] were significantly altered in HCC (11).
Their study showed that hepatic perfusion, BV, HPI, and
AP values were higher, whereas PP and TTP were lower,
in HCCs relative to the surrounding liver. In the current
study, we could evaluate BF, BV, AP, PP, and HPI in HCC
and normal liver parenchyma, and the results were similar
to those of the previous study. In our study, we assessed the
potential role of CT perfusion imaging in the evaluation of
HCC lesions. According to our results, this study showed
that the values of perfusion parameters, particularly BF,
BV, AP, and HPI, are higher in the lesion compared to the
normal liver parenchyma.
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Figure. CT perfusion images show the ROIs of normal liver parenchyma (1) and HCC (2). The perfusion parameters of liver (BF, BV,
AP, HPI, and PP) are shown in the normal liver parenchyma (1) and HCC (2) (for abbreviations, refer to the text).

Table. Values of perfusion parameters of the patients in normal liver parenchyma and HCC (mean ± standard deviation).
Perfusion parameters

Liver parenchyma

Hepatocellular carcinoma

BF, mL 100 mL–1 min–1

27.29 ± 13.23

58.17 ± 18.52

BV, mL 100 mL

9.07 ± 3.27

16.72 ± 6.31

AP, mL 100 mL–1 min–1

8.17 ± 6.35

59.77 ± 27.12

PP, mL 100 mL min

17.53 ± 5.71

0.13 ± 0.09

HPI, %

27.46 ± 23.87

96.85 ± 12.25

–1

–1

–1

BF: Blood flow; BV: Blood volume; AP: Arterial perfusion; PP: Portal perfusion; HPI: Hepatic perfusion index.
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There were some limitations to this study. First, the
study had a small group of patients. Second, CT perfusion
parameters were not compared with the other markers
of angiogenesis, such as microvessel density. Third, the
radiation dose for each patient was not assessed, although
the estimated effective radiation dose was 6.3–7.2 mSv, on
the basis of the parameters used.

This study shows that CT perfusion imaging is a
useful tool that may serve as a noninvasive biomarker
of angiogenesis. CT perfusion imaging has the ability
to evaluate tumor assessment, characterization, and
neoangiogenesis, and may even play a role in tumor
staging in HCC.
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